Equity Research, Broker Reports, and media content on IPSEN

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about IPSEN
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on IPSEN. We currently have 5 research reports from 1 professional analysts.

Date Source Announcement
10Nov16 01:30 PRN IPSEN to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 16th, 2016
10Nov16 01:00 PRN International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2016
26Oct16 02:00 PRN Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society
19Oct16 01:00 PRN Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the Annual Meeting of the American Academy of Physical Medicine & Rehabilitation
30Sep16 02:05 PRN Ipsen Biopharmaceuticals, Inc. Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium
21Sep16 06:54 PRN Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine
03Aug16 08:37 PRN Multimedia Assets Now Available: Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older
  • Frequency of research reports

     

  • Research reports on

    IPSEN

  • Providers covering

    IPSEN

Latest Content

View the latest research, videos, and podcasts for this company.

Solid financial performance; new mid-term growth engine instilled by the CEO

  • 12 Jan 17

Ipsen reported yet another strong quarter. The revenue for Q3 FY16 (at CER unless specified otherwise) increased by 12.2% (vs Q2 16: +14.5%), fuelled by strong growth in the speciality care ‘SC’ segment (+17.8% vs Q2 16: +18.6%; accounts for c.82% of Q3 16 sales). Within the segment, Somatuline was the largest growth contributor (+34.1% vs Q2 16: +37.4%; accounts for c.35% of Q3 16 sales), and once again drove the robust volume growth and favourable pricing trend in the North America. Moreover, the good overall performance in Europe (notably Germany, France, and the UK) further underpinned the sales of the drug. The impressive performance continued for ‘Decapeptyl’ (+6.3% vs Q2 16: +6.7%; accounts for c.22% of Q3 16 sales), aided by a strong volume uptick in Europe. Growth for Dysport decelerated to +9.3% (vs Q2 16: +12.2%; accounts for c.19% of Q3 16 sales) as the solid performance in the US aesthetics market was slightly offset by volume declines in Brazil and Russia. The dismal performance continued in the primary care ‘PC’ segment (-7.5% vs Q2 16: -0.1%; accounts for c.18% of Q3 16 sales), mainly due to the slower ramp-up of the new commercial strategy in China for Smecta (-1% vs Q2 16: +1.7%; accounts for c.6% of Q3 16 sales). Moreover, the challenging market environment for Tanakan in Russia and for Forlax in Algeria, suppressed further growth in the segment. Geographically, revenue was up 6% in major western European countries (vs Q2 16: +9.2%; accounts for c.35% of Q3 16 sales) and +4.4% in other European countries (vs Q2 16: +12.2%; accounts for c.21% of Q3 16 sales). Sales in North America increased by 72% (vs Q2 16: +75.3%; accounts for c.18% of Q3 16 sales), driven by the solid performance of key drugs – Somatuline and Dysport. ROW was up 1.8% (Q2 16: +1.1%; accounts for c.26% of Q3 16 sales). The total reported revenue grew by 10.2% (vs Q2 16: +10.5%), reflecting a -2% currency effect. Management has raised the FY16 revenue guidance for the SC business (+15% vs earlier guidance of +12%) subsequent to the strong performance witnessed in 9M FY16. Although the revenue guidance for the PC business has been lowered to c.-5% (vs slight growth earlier), Ipsen’s core operating margin guidance has been revised upwards by 100bp (vs earlier guidance). In August 2016, the US FDA approved Dysport for the treatment of paediatric lower limb (PLL) spasticity and, in September 2016, the European Commission approved cabometyx as a second line of treatment for renal cell carcinoma (RCC). Moreover, in October 2016, Ipsen (along with partner Exelixis) announced positive clinical data from its ‘Cabosun’ phase 2 trial (for use of Cabometyx in the frontline setting for RCC). In January 2017, Ipsen acquired US commercialisation rights for oncology drug ‘Onivyde’, from Merrimack Pharma. The drug is approved as a second-line of treatment for metastatic pancreatic cancer and is the only FDA approved drug in this indication (post gemcitabine-based therapy). The deal (expected to close in Q1 17) involves payment of $575m in cash and up to $450m in additional milestones, contingent upon the approval of Onivyde for other potential indications in the US.